| Code | CSB-RA013047MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ABBV-142, targeting lysophosphatidic acid receptor 1 (LPAR1), also known as LPA1 or EDG2. LPAR1 is a G protein-coupled receptor that mediates cellular responses to lysophosphatidic acid (LPA), a bioactive phospholipid involved in diverse physiological processes including cell proliferation, migration, survival, and cytoskeletal reorganization. LPAR1 signaling plays critical roles in embryonic development, particularly neural tube formation, and has been implicated in various pathological conditions. Dysregulated LPAR1 activity is associated with fibrotic diseases affecting the lung, liver, and kidney, as well as neuropathic pain, cancer progression, and cardiovascular disorders.
ABBV-142 represents a therapeutic antibody developed to modulate LPAR1 signaling, with particular investigation in fibrotic conditions such as idiopathic pulmonary fibrosis. This biosimilar provides researchers with a valuable tool for investigating LPAR1-mediated pathways, studying the receptor's role in disease pathogenesis, and exploring potential therapeutic interventions targeting LPA-LPAR1 signaling in preclinical models.
There are currently no reviews for this product.